Key Development
A chronic-disease patient may see a physician only a few times a year, but medication use and self-management happen every day. The space between medical appointments is increasingly becoming a new healthcare market for retail pharmacies.
On September 20, 2026, Pharmacity launched its Chronic Disease Healthy Living Club, targeting patients, families and caregivers. According to the company, the model combines membership benefits with pharmacist counselling, basic health monitoring, home medication delivery, medication reminders, prescription-history storage, medical information and digital doctor Q&A programs.
Pharmacity says it now operates more than 1,100 GPP-standard pharmacies with nearly 5,000 pharmacists. Its wider network already supports blood-pressure, blood-glucose and BMI measurements, gout screening and selected community-health activities. The new club also involves healthcare professionals, hospitals and pharmaceutical companies including Bayer and AstraZeneca.
Why It Matters
- Chronic disease creates recurring care needs rather than one-off transactions. Noncommunicable diseases account for approximately 80% of deaths in Vietnam.
- Proximity increasingly matters in chronic care. WHO estimates that about 18 million people in Vietnam live with hypertension. Community-based programs now screen around 10 million people annually and have brought more than two million into treatment.
- Pharmacies have a frequency advantage. Patients may collect medicines or health products much more often than they visit hospitals, creating repeated opportunities for adherence support and escalation when problems emerge.
- Digital engagement converts transactions into longitudinal relationships. Medication reminders, prescription history and health tracking can maintain contact after a customer leaves the store.
Healthcare Insight Analysis
Healthcare Insight believes the strategic signal is not the word “club.”
It is Pharmacity’s attempt to change the economics of pharmacy retail.
Traditional pharmacy optimizes a transaction: a consumer needs a product, buys it and leaves.
Chronic care requires the opposite model: maintain a relationship with the same patient for years.
If Pharmacity can combine pharmacists, prescription histories, medication reminders, basic monitoring and more than 1,100 physical locations into a consistent patient-support layer, its value proposition could move beyond store traffic.
Commercially, that could mean stronger retention and higher customer lifetime value.
Clinically, the more important possibility is improved medication persistence and earlier identification of patients who need professional medical review.
The strategy also fits a broader shift in Vietnam toward community-based management of noncommunicable diseases. In the WHO-supported hypertension program, blood-pressure control among participating patients increased from 53% in 2022 to 72% in 2025.
But a private pharmacy network is not a primary-care clinic, and it should not be evaluated as one.
Its most credible role is medication adherence support, medicine education, basic monitoring and referral. Pharmacity itself explicitly states that pharmacies cannot replace physicians or healthcare facilities.
That boundary will determine whether the club generates genuine healthcare value or becomes a more sophisticated loyalty program.
A blood-pressure reading, for example, matters only if an abnormal result triggers an appropriate escalation pathway. A medication reminder matters if it improves persistence. A prescription-history database becomes clinically useful only when it is accurate, secure and supports safer pharmacist counselling.
There is also a structural tension that deserves attention: commercial incentives and health support now sit inside the same retail environment.
Pharma participation can bring useful disease education and patient-support resources, but governance must clearly separate education and adherence support from inappropriate product promotion.
For that reason, membership should not be the most important KPI.
More meaningful measures would include medication refill persistence, timely follow-up, referrals after abnormal screening, pharmacist interventions and changes in measurable disease-control indicators.
Market Implications
Pharmacity: can shift from a retail relationship toward a recurring healthcare relationship, potentially strengthening loyalty and lifetime value. Sustainable differentiation, however, will depend on clinical governance as much as CRM.
Pharmaceutical companies: gain an additional channel for disease education, adherence initiatives and patient support. Compliance standards will become increasingly important as commercial and clinical touchpoints converge.
Hospitals and physicians: pharmacy networks could provide a useful layer between appointments when referral pathways are clearly defined, particularly for hypertension, diabetes and other long-term medication-dependent conditions.
Healthtech companies: medication-reminder tools, connected monitoring devices, prescription-history platforms and patient-engagement software gain access to a large physical distribution network.
Two signals matter next: whether Pharmacity begins publishing health-outcome metrics rather than primarily membership metrics, and whether the model develops structured referral and data pathways with healthcare providers rather than remaining contained within the retail ecosystem.
If it does, the Chronic Disease Healthy Living Club could become more than a loyalty initiative. It would test whether Vietnam’s pharmacy chains can become a meaningful layer of continuous care between the patient and the formal healthcare system.